New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BV;BBY;CYTX;ALXA;ZQK;ADBE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
09:46 EDTBBYBest Buy management to meet with JPMorgan
Subscribe for More Information
February 26, 2015
12:04 EDTBBYBest Buy volatility increases into Q4 and outlook
Best Buy March weekly call option implied volatility is at 60, March is at 42, April is at 35, June is at 34; compared to its 26-week average of 41 according to Track Data, suggesting large near term price movement into the expected release Q4 results on March 3.
08:02 EDTCYTXCytori Therapeutics says receives FDA approval to expand Scleroderma trial
Cytori Therapeutics announced that it received approval from FDA to expand the number of Scleroderma clinical trial sites from 12 to 20 centers in the United States. The STAR study is an 80 patient pivotal clinical trial approved by FDA in January to study the effects of Cytori’s lead drug ECCS-50 for treatment of patients with hand manifestations of Scleroderma.
February 24, 2015
08:17 EDTCYTXCytori Therapeutics receives positive European opinion on orphan drug status
Subscribe for More Information
February 23, 2015
08:00 EDTADBEAdobe shares recommended at Rosenblatt
Rosenblatt believes Adobe continues to execute and will report Q1 earnings and revenues slightly ahead of consensus estimates of 40c/1.09B and for new sub adds and Marketing Cloud billing to be above expectations.
February 18, 2015
09:32 EDTBBYComarco files patent suit against Best Buy
Subscribe for More Information
February 17, 2015
08:03 EDTCYTXCytori Therapeutics begins enrollment in Phase II ACT-OA trial
Cytori Therapeutics announced that the first patient has been treated in its FDA approved trial assessing the effect of Cytori Cell Therapy for osteoarthritis of the knee. The patient was treated by Dr. Peter Hanson, Medical Director of Orthopedic Surgery at Sharp Grossmont Hospital. ACT-OA is a Phase II FDA approved randomized, double-blind, placebo controlled trial in 90 patients evaluating the efficacy and safety of Cytori’s autologous adipose derived therapy ECCO-50 (Cytori’s therapeutic under study). The trial tests both a low dose and a high dose vs. placebo and will be conducted over 48 weeks. The randomization will be 1:1:1 between the control, low dose and high dose groups. The primary end point will be pain on walking as measured by the Knee Injury and Osteoarthritis Outcome Score at 12 weeks. Secondary endpoints assessed will include pain, joint function, magnetic resonance imaging and adverse events.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use